Loading organizations...
§ Private Profile · Redwood City, CA, USA
Biopharmaceutical company developing sustained-release therapies for ocular diseases, including retinal conditions.
GrayBug Vision was a clinical-stage biopharmaceutical company focused on developing transformative, sustained-release therapies for various ocular diseases, including neovascular age-related macular degeneration, operating from Redwood City, California, and Baltimore, Maryland. The company's core approach involved injectable controlled-release technologies, leveraging micro and nanoparticle systems to reduce the burden of frequent injections, aiming for dosing frequencies as low as twice per year. GrayBug became a publicly traded entity on Nasdaq, listing under the ticker GRAY in September 2020. Its foundational technology was licensed from the Johns Hopkins University School of Medicine, and early investors included Hatteras Venture Partners. The company underwent a significant change in March 2023, announcing a merger that led to a name change to CalciMedica, Inc. and a new trading symbol, CALC, effective March 21, 2023. GrayBug was founded in 2011.
GrayBug has raised $127.0M across 3 funding rounds.
GrayBug has raised $127.0M in total across 3 funding rounds.
GrayBug has raised $127.0M across 3 funding rounds. Most recently, it raised $80.0M Series C in August 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2019 | $80M Series C | Michael Keyoung | Hatteras Venture Partners, Deerfield Management, OrbiMed | Announced |
| May 1, 2016 | $45M Series B | Cameron Wheeler | Hatteras Venture Partners | Announced |
| Mar 1, 2015 | $2M Series A | Hatteras Venture Partners, Maryland Venture Fund | — | Announced |
GrayBug has raised $127.0M in total across 3 funding rounds.
GrayBug's investors include Michael Keyoung, Hatteras Venture Partners, Deerfield Management, OrbiMed, Cameron Wheeler, Maryland Venture Fund.
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company specializing in innovative drug delivery technologies for serious ocular diseases, primarily targeting chronic retinal and optic nerve conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. The company develops sustained-release therapies designed to improve patient compliance and clinical outcomes by reducing the frequency of treatments through controlled drug delivery systems. Its lead product candidates include GB-102 for wet AMD and GB-401 for glaucoma, both utilizing proprietary microparticle and implant technologies to provide long-term therapeutic effects[1][2][4].
Founded in 2011 as a spin-out from the Wilmer Eye Institute at Johns Hopkins University, Graybug Vision was established by experts in ophthalmology and drug delivery, including founder Justin Hanes, PhD, a prominent researcher in polymer-based drug delivery systems. The company’s origin is rooted in translating advanced controlled-release technologies into practical treatments for vision-threatening diseases. Early traction came from leveraging strong intellectual property and collaborations with academic and pharmaceutical partners, positioning Graybug as a pioneer in sustained ocular drug delivery[2][3].
Graybug Vision is riding the trend of precision, sustained-release drug delivery in ophthalmology, a field where frequent intravitreal injections pose significant patient burden and healthcare costs. The timing is critical as the global population ages and the prevalence of retinal diseases rises, increasing demand for innovative therapies that improve compliance and reduce treatment frequency. Advances in polymer science and nanotechnology underpin Graybug’s platform, positioning it at the forefront of ocular therapeutics innovation. By addressing major chronic eye diseases with novel delivery systems, Graybug influences the broader biotech ecosystem by setting new standards for drug administration and patient-centric treatment design[1][3][4].
Looking ahead, Graybug Vision is poised to advance its clinical pipeline, particularly with GB-102 and GB-401 progressing through clinical trials. The company’s focus on sustained-release therapies aligns with broader healthcare trends emphasizing long-acting treatments and improved patient adherence. Future growth may come from expanding indications, developing combination therapies, and forming strategic partnerships to accelerate commercialization. As regulatory approvals and clinical data mature, Graybug’s influence in ophthalmic drug delivery is likely to grow, potentially reshaping treatment paradigms for chronic ocular diseases and enhancing patient outcomes globally[1][4].